Camrelizumab plus nimotuzumab as second-line therapy for advanced esophageal squamous cell carcinoma: a multicenter phase II study.

Xia J, Meng X, Jiang G, Hong Y, Ji Y, Wang C, Yang X, Meng Y, Zhang W, Luo Z, Cui D, Wang J, Shan Z, Guan L, Lu Y, Yang X, Ren C, Meng X, Wang H, Shen L, Zhang Y, Kou Z, Lu T, Fan Q, Quante M, Zhao T, Li S, Wang F

Open source

DOI: 10.1136/jitc-2026-015887
Published: 2026 Sep 8
Container: Journal for immunotherapy of cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2026-015887,
  title = {Camrelizumab plus nimotuzumab as second-line therapy for advanced esophageal squamous cell carcinoma: a multicenter phase II study.},
  author = {Xia J and Meng X and Jiang G and Hong Y and Ji Y and Wang C and Yang X and Meng Y and Zhang W and Luo Z and Cui D and Wang J and Shan Z and Guan L and Lu Y and Yang X and Ren C and Meng X and Wang H and Shen L and Zhang Y and Kou Z and Lu T and Fan Q and Quante M and Zhao T and Li S and Wang F},
  year = {2026},
  journal = {Journal for immunotherapy of cancer},
  doi = {10.1136/jitc-2026-015887},
  url = {https://doi.org/10.1136/jitc-2026-015887}
}

RIS

TY  - JOUR
TI  - Camrelizumab plus nimotuzumab as second-line therapy for advanced esophageal squamous cell carcinoma: a multicenter phase II study.
AU  - Xia J
AU  - Meng X
AU  - Jiang G
AU  - Hong Y
AU  - Ji Y
AU  - Wang C
AU  - Yang X
AU  - Meng Y
AU  - Zhang W
AU  - Luo Z
AU  - Cui D
AU  - Wang J
AU  - Shan Z
AU  - Guan L
AU  - Lu Y
AU  - Yang X
AU  - Ren C
AU  - Meng X
AU  - Wang H
AU  - Shen L
AU  - Zhang Y
AU  - Kou Z
AU  - Lu T
AU  - Fan Q
AU  - Quante M
AU  - Zhao T
AU  - Li S
AU  - Wang F
PY  - 2026
JO  - Journal for immunotherapy of cancer
DO  - 10.1136/jitc-2026-015887
UR  - https://doi.org/10.1136/jitc-2026-015887
ER  -

APA

J, X., X, M., G, J., Y, H., Y, J., C, W., X, Y., Y, M., W, Z., Z, L., D, C., J, W., Z, S., L, G., Y, L., X, Y., C, R., X, M., H, W., L, S., Y, Z., Z, K., T, L., Q, F., M, Q., T, Z., S, L., & F, W. (2026). Camrelizumab plus nimotuzumab as second-line therapy for advanced esophageal squamous cell carcinoma: a multicenter phase II study.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2026-015887

Source records

pubmed · retrieved 2026-09-25T19:07:57.917Z